Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001051026 | SCV001215159 | benign | Idiopathic generalized epilepsy; Hyperaldosteronism, familial, type IV | 2023-08-17 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004800674 | SCV005423029 | uncertain significance | not specified | 2024-10-07 | criteria provided, single submitter | clinical testing | Variant summary: CACNA1H c.5665G>A (p.Gly1889Arg) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 3.1e-05 in 159120 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. To our knowledge, no occurrence of c.5665G>A in individuals affected with Idiopathic Generalized Epilepsy and no experimental evidence demonstrating its impact on protein function have been reported. ClinVar contains an entry for this variant (Variation ID: 847473). Based on the evidence outlined above, the variant was classified as uncertain significance. |
Ambry Genetics | RCV004963040 | SCV005552809 | uncertain significance | Inborn genetic diseases | 2024-09-26 | criteria provided, single submitter | clinical testing | The c.5665G>A (p.G1889R) alteration is located in exon 33 (coding exon 32) of the CACNA1H gene. This alteration results from a G to A substitution at nucleotide position 5665, causing the glycine (G) at amino acid position 1889 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |